News Daily News Higher Single-Sample hs-cTnT Threshold Can Safely Exclude MI Michael O'Riordan May 13, 2022
News Daily News The Hunt for Protein Culprits in COVID-19’s Cardiac Complications Michael O'Riordan May 06, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Daily News Age and Fitness Biggest Predictors of Mortality in CAD Patients, AI Study Shows Michael O'Riordan May 04, 2022
News Daily News NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes L.A. McKeown May 03, 2022
News Conference News HRS 2022 Intensive BP Control May Stave Off LV Conduction Disease: SPRINT Todd Neale May 02, 2022
News Daily News FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy Michael O'Riordan April 29, 2022
News Daily News Cardio-Obstetrics Merits Better Training, Wider Uptake: Survey Caitlin E. Cox April 26, 2022
News Daily News Don’t Rule Out CABG for Elderly Patients With Multiple Comorbidities Michael O'Riordan April 25, 2022
News Daily News CVD Hospitalizations Spiked in Aftermath of 2020 US Election Michael O'Riordan April 22, 2022
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery Todd Neale April 06, 2022
Presentation ACC 2022 A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF Presenter: Tariq Ahmad April 04, 2022
News Conference News ACC 2022 CHAP: Better Blood Pressure Control, Better Pregnancy Outcomes Michael O'Riordan April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022